Group 1 - The stock price of Shanxi Jinbo Biopharmaceutical Co., Ltd. has reached a historical high, with a cumulative increase of over 150% this year, driven by its scarcity in the A-share market and rapid performance growth [1] - The North Exchange 50 Index has also reached a historical high, with a maximum cumulative increase of over 10% in May, and the market trading volume has consistently remained above 30 billion yuan [1] Group 2 - There is a growing expectation for the institutional dividends of the North Exchange, supported by recent favorable policies and messages, which provide a foundation for long-term market development [2] - The leadership from Beijing and the China Securities Regulatory Commission (CSRC) has emphasized the need to deepen reforms at the North Exchange and improve institutional design for healthy and rapid development [2][3] Group 3 - The North Exchange is becoming a key area for innovative small and medium-sized enterprises, with a focus on enhancing capital service capabilities for these companies [3] - The North Exchange has shown unique investment attractiveness, particularly for specialized and innovative "little giant" enterprises, which are expected to stand out in future technology cycles [4] Group 4 - As of the end of Q1 2025, public fund allocations to the North Exchange reached a record high of 6.743 billion yuan, an increase of 24.45% from the end of 2024, with 34 public fund institutions participating [4] - The scale of the North Exchange 50 Index fund reached 9.539 billion yuan as of April 30, 2025, reflecting a year-on-year growth of 22.63% [5] Group 5 - All 11 North Exchange thematic funds reported positive returns in 2025, with an average return of 33.48% year-to-date [5] - Despite the overall strong performance of the North Exchange, industry differentiation is expected to become the norm, with a focus on sectors like artificial intelligence and robotics [6]
北交所锦波生物股价再创新高，制度红利预期不断升温个股持续活跃